Results for: Guidance

Super Micro Computer Inc. reported fiscal third-quarter revenue that fell short of expectations, but the server maker raised its outlook for the year, sending shares higher in extended trading. The company earned $6.65 per share, excluding items, on revenue of $3.85 billion. Analysts surveyed by Refinitiv had expected $5.78 per share on revenue of $3.95 billion. Super Micro’s revenue jumped 200% year over year, compared with a 103% increase in the previous quarter. The company now expects fiscal 2024 revenue of $14.7 billion to $15.1 billion, up from a previous range of $14.3 billion to $14.7 billion.

Meta Platforms delivered a strong first quarter, surpassing estimates for revenue, earnings, and cash flow. However, guidance concerns, including a conservative revenue outlook and increased capital expenditures, overshadowed the positive results, sending shares tumbling in after-hours trading. Despite the post-earnings sell-off, analysts maintain a bullish outlook, citing Meta’s dominance in targeted advertising and its potential to lead in artificial intelligence (AI) and other emerging technologies.

Align Technology (NASDAQ: ALGN) released strong first-quarter results, exceeding analyst estimates for both earnings and revenue.

The company reported earnings per share (EPS) of $2.14, significantly higher than the consensus estimate of $1.97. Revenue for the quarter came in at $997.4 million, surpassing the consensus estimate of $974.53 million.

In terms of guidance, Align projects second-quarter 2024 revenue between $1.03 billion and $1.05 billion, in line with the analyst consensus of $1.03 billion. The company’s stock price closed at $313.78, showing an 18.73% increase in the last three months and a 10.74% decline in the last 12 months.

Boston Scientific Corporation (BSX) reported impressive first-quarter earnings, exceeding analyst expectations. The company’s revenue reached $3.86 billion, surpassing the estimated $3.69 billion. Sales experienced significant growth across all segments, with the cardiovascular segment leading the way with a rise of over $2.4 billion. Boston Scientific also raised its 2024 guidance, forecasting net sales growth of 11%-13% and adjusted EPS of $2.29-$2.34, both higher than previous estimates. The company’s strong performance and positive outlook contributed to a 6.02% surge in BSX shares, reaching $73.15 during Wednesday’s trading session.

Thermo Fisher Scientific Inc. reported mixed financial results for the first quarter of 2024, with revenue beating estimates but organic growth declining. Revenue came in at $10.34 billion, a 3% decrease year-over-year but above the consensus of $10.17 billion. Adjusted earnings per share (EPS) of $5.11 surpassed expectations of $4.71 and increased from $5.03 in the prior year quarter. Despite revenue declines in certain segments, the company’s strong commercial execution and operational discipline drove overall performance. Thermo Fisher raised its full-year 2024 guidance, projecting revenue between $42.3 billion and $43.3 billion and adjusted EPS between $21.14 and $22.02.

Novartis AG (NVS) reported strong first-quarter results, leading the company to raise its full-year guidance. Adjusted EPS increased 17% year over year to $1.80, surpassing the consensus estimate of $1.67. Sales reached $11.83 billion, exceeding the consensus of $11.43 billion. Key growth drivers included the heart failure drug Entresto, the psoriasis drug Cosentyx, and the cancer drug Pluvicto. Novartis also announced that Giovanni Caforio will be proposed as the next chair of the board of directors. The company now expects net sales growth in the high-single to low-double-digit percentage range and core operating income growth in the low double-digit to mid-teens percentage range for 2024.

Automotive parts company LKQ (NASDAQ:LKQ) reported financial results for the first quarter of calendar year 2024 (Q1 CY2024), missing analysts’ expectations. Despite a 10.6% year-over-year increase in revenue to $3.70 billion, the company’s non-GAAP earnings per share (EPS) of $0.82 fell short of the estimated $0.95, marking a 13.8% miss. LKQ’s full-year guidance for adjusted EPS and free cash flow was maintained, while organic sales guidance was lowered.

Food and beverage giant PepsiCo (NASDAQ: PEP) reported mixed financial results for the first quarter of its 2024 fiscal year. While revenue and earnings per share (EPS) exceeded analysts’ expectations, the company missed on its operating and gross margins.

Total revenue increased by 2.3% year-on-year to $18.25 billion, slightly above the consensus estimate of $18.11 billion. Non-GAAP EPS came in at $1.61, surpassing the expected $1.52, marking a 6% beat.

Despite the revenue growth, PepsiCo’s sales volumes declined by 2% year-on-year, indicating a challenge in driving product demand. However, the company was able to offset this decline through price increases, resulting in organic revenue growth of 2.7%.

The company maintained its full-year guidance from the previous quarter, with full-year non-GAAP EPS guidance remaining in line with consensus estimates. PepsiCo’s stock price remained flat after the earnings announcement, currently trading at $175.11 per share.

Lockheed Martin Corporation (NYSE: LMT) reported better-than-expected first-quarter 2023 financial results, driven by solid growth in its various business segments. The company also raised its full-year earnings guidance, reflecting its confidence in its business outlook.